Epigral, a midcap player in the chemicals industry, has recently faced a downgrade in its stock call to 'Sell' by MarketsMOJO as of December 23, 2024. The downgrade is attributed to an expensive valuation, highlighted by a Return on Capital Employed (ROCE) of 22.1 and an Enterprise Value to Capital Employed ratio of 4. Despite trading at a discount compared to its historical valuations, the stock has shown significant performance over the past year, generating a return of 113.05% alongside a profit increase of 31.4%. The company's Price/Earnings to Growth (PEG) ratio stands at 1.1.
In terms of growth metrics, Epigral has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 6.37% and operating profit soaring by 75.76%. The company reported net sales of Rs 1,277.26 crore for the half-year, reflecting a growth of 36.89%. Additionally, the debt-equity ratio is at a low 0.64 times, indicating a strong balance sheet. However, the technical trend is currently sideways, showing no clear price momentum, and has deteriorated from a mildly bullish stance, resulting in a -1.9% return since the downgrade.
Daily News Updates
